Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

BACKGROUND: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and elevated cardiovascular risk. The comparative effects among parti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Circulation
Egile Nagusiak: Mahaffey, Kenneth W., Neal, Bruce, Perkovic, Vlado, de Zeeuw, Dick, Fulcher, Greg, Erondu, Ngozi, Shaw, Wayne, Fabbrini, Elisa, Sun, Tao, Li, Qiang, Desai, Mehul, Matthews, David R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott Williams & Wilkins 2018
Gaiak:
Original Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777572/
https://ncbi.nlm.nih.gov/pubmed/29133604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.117.032038
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak